Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

  • Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse
  • Well+Good says psychedelics “poised to change the course of mental health treatment”
  • Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process

A USA Today article is touting psychedelics as the next big thing in mental health treatment ( This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE American: CYBN) has been working toward since the company started: a strategic psychedelics to therapeutics model that will transform the mental health space. 

“If you haven’t heard about psychedelics being used as a treatment for mental health disorders, this year may change that,” the article stated. “While this type of treatment won’t be accessible to everyone in 2022 (and will likely take a while to become widespread), experts say you should expect to hear much more about this emerging wellness trend this year and beyond.

“‘For a long time, psychedelics have been sort of frowned upon,’ says Amy Morin, psychotherapist and editor-in-chief at VeryWell Mind. ‘We thought they were more recreational drugs, but with a closer look, we’ve seen they can actually be really good treatments for things like depression, anxiety, even substance abuse issues.’”

The article noted that Dr. Matthew W. Johnson, a professor of psychiatry and behavioral sciences at Johns Hopkins and acting director of the Johns Hopkins Center of Psychedelics and Consciousness Research, has seen a gradual increase in interest around psychedelics since he began focusing on them in 2004, but he said interest now is increasing dramatically; he thinks that interest will only increase moving forward. 

“In their 2022 wellness trend forecast, Well+Good dubbed psychedelics as being ‘poised to change the course of mental health treatment,’” the article stated. “Institutions are also getting ready by opening up specialized centers to study these drugs in a mental health capacity.”

This dramatic increase bodes well for one of the leaders in the psychedelic space. On a mission to revolutionize mental health care, Cybin has developed key relationships with a network of world-class partners and internationally recognized scientists as it focuses on creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is working on turning its psychedelics to therapeutics vision into reality by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. 

At the core of this transformative work is Cybin’s efforts to combine novel psychedelic molecules with controllable drug-delivery systems through its proprietary deuterated process. In doing so, the company is creating patent-protected, commercially scalable drug candidates and establishing itself as a strong player in an industry projected to see significant growth.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050